TNP-ATP (tetrasodium)

TNP-ATP is an antagonist of purinergic P2Y1, P2X3, and P2X2/3 receptors (IC50 = 6, 0.9, and 7 nM, respectively, in HEK293 cells expressing human receptors) . TNP-ATP reduces acetate-induced calcium flux in 1321N1 cells expressing P2X3 and P2X2/3 receptors (IC50 = 100 and 62 nM, respectively) . TNP-ATP dose-dependently attenuates acetate-induced abdominal contractions in a mouse visceral pain model (ED50 = 6.35 µmol/kg) [1][2].

Product Specifications

UNSPSC

12352005

Target

P2X Receptor; P2Y Receptor

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

O=[N](C(C1(C([N](=O)=O)=C2)O[C@]([C@@](N3C4=NC=NC(N)=C4N=C3)([H])O[C@@H]5CO[P](O[P](O[P](O[Na])(O[Na])=O)(O[Na])=O)(O[Na])=O)([H])[C@]5([H])O1)=CC2[N](=O)=O)=O

Molecular Formula

C16H13N8Na4O19P3

Molecular Weight

806.20

References & Citations

[1]Honore P, et al. TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics. Pain. 2002 Mar;96 (1-2) :99-105.|[2]Virginio C, et al. Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53 (6) :969-73.